BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23585862)

  • 21. Serum Protein Markers for the Early Detection of Lung Cancer: A Focus on Autoantibodies.
    Broodman I; Lindemans J; van Sten J; Bischoff R; Luider T
    J Proteome Res; 2017 Jan; 16(1):3-13. PubMed ID: 27769114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer.
    Zhao H; Zhang X; Han Z; Xie W; Yang W; Wei J
    Sci Rep; 2018 Jun; 8(1):9847. PubMed ID: 29959381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autoantibodies against tumor-associated antigens in the early detection of lung cancer.
    Dai L; Tsay JC; Li J; Yie TA; Munger JS; Pass H; Rom WN; Zhang Y; Tan EM; Zhang JY
    Lung Cancer; 2016 Sep; 99():172-9. PubMed ID: 27565936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer.
    Zhu W; Zhou K; Zha Y; Chen D; He J; Ma H; Liu X; Le H; Zhang Y
    PLoS One; 2016; 11(4):e0153046. PubMed ID: 27093275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a Protein Biomarker Panel to Detect Non-Small-Cell Lung Cancer in Korea.
    Jung YJ; Katilius E; Ostroff RM; Kim Y; Seok M; Lee S; Jang S; Kim WS; Choi CM
    Clin Lung Cancer; 2017 Mar; 18(2):e99-e107. PubMed ID: 27836219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical significance and diagnostic value of Survivin autoantibody in non-small cell lung cancer patients].
    Ma L; Yue W; Zhang L; Wang Y; Zhang C; Yang X
    Zhongguo Fei Ai Za Zhi; 2010 Jul; 13(7):706-12. PubMed ID: 20673487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer.
    Du Q; Yu R; Wang H; Yan D; Yuan Q; Ma Y; Slamon D; Hou D; Wang H; Wang Q
    Clin Respir J; 2018 Jun; 12(6):2020-2028. PubMed ID: 29356386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer.
    Xie Y; Zhang Y; Du L; Jiang X; Yan S; Duan W; Li J; Zhan Y; Wang L; Zhang S; Li S; Wang L; Xu S; Wang C
    Mol Oncol; 2018 May; 12(5):648-658. PubMed ID: 29504701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma.
    Chen G; Wang X; Yu J; Varambally S; Yu J; Thomas DG; Lin MY; Vishnu P; Wang Z; Wang R; Fielhauer J; Ghosh D; Giordano TJ; Giacherio D; Chang AC; Orringer MB; El-Hefnawy T; Bigbee WL; Beer DG; Chinnaiyan AM
    Cancer Res; 2007 Apr; 67(7):3461-7. PubMed ID: 17409457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of lung cancer biomarkers by profiling the plasma proteome with monoclonal antibody libraries.
    Guergova-Kuras M; Kurucz I; Hempel W; Tardieu N; Kádas J; Malderez-Bloes C; Jullien A; Kieffer Y; Hincapie M; Guttman A; Csánky E; Dezso B; Karger BL; Takács L
    Mol Cell Proteomics; 2011 Dec; 10(12):M111.010298. PubMed ID: 21947365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis.
    Tang ZM; Ling ZG; Wang CM; Wu YB; Kong JL
    PLoS One; 2017; 12(7):e0182117. PubMed ID: 28750095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum pleiotrophin could be an early indicator for diagnosis and prognosis of non-small cell lung cancer.
    Du ZY; Shi MH; Ji CH; Yu Y
    Asian Pac J Cancer Prev; 2015; 16(4):1421-5. PubMed ID: 25743809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum chemokine network correlates with chemotherapy in non-small cell lung cancer.
    Yang D; Zhou J; Zeng T; Yang Z; Wang X; Hu J; Song Y; Chen L; Peer D; Wang X; Bai C
    Cancer Lett; 2015 Aug; 365(1):57-67. PubMed ID: 25976768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [OLC1 protein levels in plasma of patients with non-small cell lung cancer and its clinical application].
    Yang L; Xiao T; Tan J; Chen S; Gao Y; Cheng S; Liu X; Sun K
    Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):362-5. PubMed ID: 25030592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Combination of IgA and IgG autoantibodies against Transcriptional Intermediary Factor-1γ contributes to the early diagnosis of Lung Cancer.
    Yu L; Lin X; Zhang L; Wu Q; Zhang S; Chen D; Pan X; Huang Y
    Int J Med Sci; 2020; 17(11):1561-1568. PubMed ID: 32669959
    [No Abstract]   [Full Text] [Related]  

  • 36. Potential circulating miRNA signature for early detection of NSCLC.
    Arab A; Karimipoor M; Irani S; Kiani A; Zeinali S; Tafsiri E; Sheikhy K
    Cancer Genet; 2017 Oct; 216-217():150-158. PubMed ID: 29025589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and Validation of Serum Autoantibodies Against Tumor-Associated Antigens as Biomarkers in Gastric Adenocarcinoma Based on the Focused Protein Arrays.
    Yang Q; Qin J; Sun G; Qiu C; Jiang D; Ye H; Wang X; Dai L; Zhu J; Wang P; Zhang J
    Clin Transl Gastroenterol; 2020 Dec; 12(1):e00284. PubMed ID: 33346593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum midkine as non-invasive biomarker for detection and prognosis of non-small cell lung cancer.
    Stern L; Mueller E; Bellon E; Reeh M; Grotelueschen R; Guengoer C; Melling N; Goetz M; Perez DR; Izbicki JR; Rawnaq-Möllers T; Ghadban T
    Sci Rep; 2021 Jul; 11(1):14616. PubMed ID: 34272441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The diagnostic value of a seven-autoantibody panel and a nomogram with a scoring table for predicting the risk of non-small-cell lung cancer.
    Wang W; Zhuang R; Ma H; Fang L; Wang Z; Lv W; Hu J
    Cancer Sci; 2020 May; 111(5):1699-1710. PubMed ID: 32108977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
    Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
    J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.